Biogen Inc. BIIB
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +41.49%
- 1 year
- +61.41%
- Open
- 253.81
- Prev close
- 253.62
- Mkt cap
- 36.81B
- Vol
- 1.17M
- Avg vol
- 1.04M
- EPS
- 2.31
- P/E
- 107.80
- Div yield
- 0.00%
More statistics
- Low
- 247.91
- High
- 255.53
- Forward P/E
- 15.29
- Beta
- 0.09
- Short ratio
- 4.46
- Inst. own
- 99.78%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 5, 2027
- 50-d avg
- 227.08
- 200-d avg
- 201.18
- 1y target
- 264.23
5D chart
Events in this range
- Oct 28, 2026Earnings: 2.62; estimate 1.99; surprise 31.66%
- Oct 29, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Oct 29, 2026Rating: RBC Capital · Outperform → Outperform
- Oct 29, 2026Rating: Argus Research · Hold → Buy
- Oct 29, 2026Rating: Canaccord Genuity · Buy → Buy
- Nov 2, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Nov 2, 2026Rating: Guggenheim · Buy → Buy
Signals (156)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 3:35 PM | 13 hours ago |
| SMA: Bullish | Nov 2, 3:35 PM | 13 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 13 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 13 hours ago |
| SMA: Bullish | Nov 2, 3:05 PM | 13 hours ago |
| SMA: Bullish | Nov 2, 2:55 PM | 14 hours ago |
| SMA: Bearish | Nov 2, 2:35 PM | 14 hours ago |
| SMA: Bullish | Nov 2, 2:30 PM | 14 hours ago |
| MACD: Buy Signal | Nov 2, 2:30 PM | 14 hours ago |
| SMA: Bearish | Nov 2, 2:05 PM | 14 hours ago |
| SMA: Bullish | Nov 2, 2:00 PM | 14 hours ago |
| MACD: Sell Signal | Nov 2, 1:30 PM | 15 hours ago |
| SMA: Bearish | Nov 2, 12:40 PM | 16 hours ago |
| SMA: Bullish | Nov 2, 12:35 PM | 16 hours ago |
| SMA: Bearish | Nov 2, 12:30 PM | 16 hours ago |
| SMA: Bullish | Nov 2, 12:05 PM | 16 hours ago |
| MACD: Buy Signal | Nov 2, 12:05 PM | 16 hours ago |
| MACD: Sell Signal | Nov 2, 12:00 PM | 16 hours ago |
| SMA: Bearish | Nov 2, 11:55 AM | 17 hours ago |
| SMA: Bullish | Nov 2, 11:45 AM | 17 hours ago |
Newest 20 of 156.
News
-
19 hours ago benzinga.com
Guggenheim Maintains Buy on Biogen, Raises Price Target to $300
Guggenheim analyst Yatin Suneja maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $280 to $300.
20 hours ago benzinga.com
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.
-
21 hours ago benzinga.com
HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $270
HC Wainwright & Co. analyst Ananda Ghosh maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $251 to $270.
3 days ago benzinga.com
Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.
-
4 days ago benzinga.com
Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $272
Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $248 to $272.
-
4 days ago benzinga.com
Argus Research Upgrades Biogen to Buy, Announces $280 Price Target
Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.
-
4 days ago benzinga.com
RBC Capital Maintains Outperform on Biogen, Raises Price Target to $272
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $256 to $272.
-
4 days ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $238
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $231 to $238.
-
4 days ago benzinga.com
TD Cowen Maintains Buy on Biogen, Raises Price Target to $260
TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $250 to $260.
-
4 days ago benzinga.com
Wedbush Maintains Neutral on Biogen, Raises Price Target to $225
Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $212 to $225.
-
4 days ago benzinga.com
Truist Securities Reiterates Buy on Biogen, Raises Price Target to $260
Truist Securities analyst Danielle Brill reiterates Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $235 to $260.
4 days ago benzinga.com
Microsoft To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for Microsoft, VF, Glaukos, Hilton, AxoGen and Brinker; Renasant’s target was cut and its rating downgraded.
4 days ago benzinga.com
These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results
Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter.
4 days ago benzinga.com
These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results
Biogen beats Q3 estimates, narrows FY2026 EPS outlook, and sees analysts raise price targets to $290; shares dip 0.3% premarket.
-
4 days ago benzinga.com
Baird Maintains Outperform on Biogen, Raises Price Target to $290
Baird analyst Brian Skorney maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $250 to $290.
-
4 days ago benzinga.com
Needham Maintains Buy on Biogen, Raises Price Target to $290
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $256 to $290.
4 days ago globenewswire.com
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab…
5 days ago marketbeat.com
Biogen Q3 Earnings Call Highlights
Biogen NASDAQ: BIIB reported third-quarter 2026 revenue growth of 11% year over year, supported by its acquisition of Apellis and continued expansion of its growth-product portfolio. Management said…
5 days ago seekingalpha.com
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript
Biogen Inc. ( BIIB ) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal -…
5 days ago zacks.com
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.
5 days ago zacks.com
Big Day for Econ Data, Hyperscaler Earnings
We have a solid slate of reports today, both of the earnings variety and regarding economic growth.
-
5 days ago benzinga.com
Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $230
Barclays analyst Emily Field maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $200 to $230.
5 days ago zacks.com
Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
5 days ago benzinga.com
Biogen Q3 2026 Earnings Call Transcript
Biogen (NASDAQ:BIIB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
5 days ago zacks.com
Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $4.81 per share a year ago.
5 days ago wsj.com
Biogen Swings to Loss, Logs Higher Sales
The biotechnology company said the swing to a loss was primarily due to transaction-related charges.
-
5 days ago benzinga.com
CORRECTION: Biogen Narrows FY2026 Adj EPS Guidance from $15.85-$16.85 to $15.95-$16.75 vs $12.36 Est
Biogen (NASDAQ:BIIB) narrows FY2026 Adj EPS guidance from $15.85-$16.85 to $15.95-$16.75 vs $12.36 analyst estimate..
-
5 days ago benzinga.com
Biogen Raises FY2026 GAAP EPS Guidance from $12.00-$13.00 to $12.20-$13.00 vs $5.84 Est
Biogen (NASDAQ:BIIB) lowers FY2026 Adj EPS guidance from $15.25-$16.25 to $12.20-$13.00 vs $12.36 analyst estimate..
-
1 week ago benzinga.com
B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244
B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.
-
1 week ago benzinga.com
TD Cowen Maintains Buy on Biogen, Raises Price Target to $250
TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $250.
-
1 week ago benzinga.com
Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310
Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $250 to $310.
-
2 weeks ago benzinga.com
Biogen To Demonstrate Data, Additional Scientific Presentations From Its Nephrology Portfolio At American Society Of Nephrology Kidney Week
Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the…
-
3 weeks ago benzinga.com
JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300
JP Morgan analyst Chris Schott upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $210 to $300.
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $260 to $256.
4 weeks ago benzinga.com
4 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
finance.yahoo.com
Should You Buy The Dip In Alnylam Stock?
Alnylam Pharmaceuticals (ALNY) stock closed at $165 on October 30, 2026, 29.5% below its October 15 close. Most of that fall ...
-
ainvest.com
Hussman Exits PepsiCo, Ubiquiti, Incyte in Sweeping Unwind
Hussman Strategic Advisors exited 159 major positions, including PepsiCo, Ubiquiti, and Incyte, during Q3 2026.
-
finance.yahoo.com
BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsight
DelveInsight's report assesses the BTK inhibitors market across the 7MM, with steady growth anticipated through 2036. This growth is driven by the increasing prevalence of B-cell malignancies, the ...
-
stocktitan.net
Biogen's Jane Grogan acquires 695 shares from award
Another 345 shares were delivered or withheld for exercise price or tax liability at $253.62 per share on October 30, 2026. The award vests annually.
-
streetinsider.com
Biogen (BIIB) PT Raised to $300 at Guggenheim
Guggenheim analyst Yatin Suneja raised the price target on Biogen (NASDAQ: BIIB) to $300.00 (from $280.00) while maintaining a Buy rating.The ...
-
marketwatch.com
Biogen Inc. stock underperforms Monday when compared to competitors
Shares of Biogen Inc. BIIB slipped 1.82% to $249.01 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.41% to…
msn.com
Regeneron Pharmaceuticals to rally around 11%? Here are 10 top analyst forecasts for Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...